ARTL
Artelo Biosciences·NASDAQ
--
--(--)
--
--(--)
6.14 / 10
Outperform
Sentiment is Outperform (6.14) and fund‑flow score excellent (8.12). Small, medium and large investors show net inflows, though overall and block trends are negative. Analyst consensus is neutral (1 analyst), reinforcing a cautious stance.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
0%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-11-19
InstitutionMaxim Group
Times predicted1
Historical Win Rate100.0%
What is the analyst consensus for ARTL?
- ARTL holds a Bearish analyst rating, with 0% of experts assigning a Hold grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 6.14/10 (Outperform).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
